高敏C-反应蛋白与2型糖尿病早期大血管病变的相关研究被引量：14

The study of relationship between high sensitivity C-reactive protein and macrovascular complications in type 2 diabetics

原文传递

导出

摘要目的探讨高敏C-反应蛋白(hsCRP)与2型糖尿病(T2DM)早期大血管病变发生的关系.方法选取2002-04～2002-10中南大学湘雅二医院170例T2DM患者给予降糖、降压、降脂等综合性治疗,其中,1年后有24例出现大血管病变,以此作为观察组;选择24例未发生大血管病变的患者作为对照组.分别比较观察组和对照组治疗前后的hsCRP变化以及观察组与对照组之间的hsCRP变化差异.结果与基线情况进行比较,1年后观察组的hsCRP水平有升高趋势,相反在对照组hsCRP水平呈下降趋势.虽然二者的差异均无统计学意义(P>0.05),但hsCRP组间差异具有显著性(P<0.05).结论 T2DM患者早期大血管病变的发生与其血浆hsCRP浓度升高有关. Objective To investigate whether high - sensitivity C - reactive protein （hsCRP） has an effect on the development of macrovascular complications in type 2 diabetics （ T2DM）. Methods One hundred and seventy patients with T2DM received comprehensive treatment for hyperglycemia, hyperlipidemia, and hypertension for one year. There were 24 individuals （observation group） in which early macrovascular complications were observed at the end of treatment. 24 diabetics without any masrovascular complications were taken as the control group. Levels of hsCRP in the two groups before and after the treatment were compared. Differences of level of hsCRP between the groups were also compared respectively. Results At the end of comprehensive treatment, it showed that the level of hsCRP in the observation group seemed to rise （ P 〉 0. 05 ） , and reversely the level of hsCRP in the control group tended to decrease （ P 〉 0. 05 ） , which led to an important difference in the levels of hsCRP between the groups （ P 〈0. 05 ）. Conclusion Our findings suggest that the level of plasma hsCRP probably relates to the development of macrovascular complications in T2DM.

作者沙永红唐炜立周智广陈小燕熊濮

机构地区吉首大学医学院中南大学湘雅二医院内分泌研究所

出处《中国实用内科杂志》 CAS CSCD 北大核心 2005年第10期890-892,共3页 Chinese Journal of Practical Internal Medicine

基金湖南省教育厅基金资助项目(04C488)

关键词 2型糖尿病大血管病变高敏C-反应蛋白 Type 2 diabetes mellitus Macrovascular complication High - sensitivity C - reactive protein

分类号 R5 [医药卫生—内科学]

引文网络
相关文献

参考文献10

1李秀钧,邬云红.糖尿病是一种炎症性疾病?[J].中华内分泌代谢杂志,2003,19(4):251-253. 被引量：254
2Alberti KG,Zimmet PZ.Definition,diagnosis and classification of diabetes mellitus and its complications.Part 1:Diagnosis and classification of diabetes mellitus-provisional report of a WHO consultation.Diabet Med,1998,15(7):539-553
3Turner RC,Millns H,Neil HA,et al.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus(UKPDS:23).BMJ,1998,31:823-828
4Ross R.Atherosclerosis:an inflammatory disease.N Engl J Med,1999,340:115-126
5Lay JI,Abraham L,Heckbert SR,et al.The relation of markers of inflammation to the development of glucose disorders in the elderly:the Cardiovascular Health Study.Diabetes,2001,50:2348-2389
6Thompson SG,Kienast J,Pyke SOM,et al.Hemostatic factors and the risk of myocardial infarction or solden death in patients with angina pectoris.N Eng J Med,1995,332(4):635-641
7Sterm MP.Diabetes and cardiovascular disease:the "common soil" hypothesis.Diabetes,1995,44:369-374
8Azen SP,Peters RK,Berkowitz K,et al.TRIPOD (Troglitazone In the Prevention of Diabetes):a randomized,placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.Control Clin Trials,1998,19:217-231
9李江,赵水平,彭道泉,许竹梅,胡敏.急性心肌梗死早期普伐他汀治疗对血浆CD40L、金属蛋白酶-9及C反应蛋白的影响[J].中华心血管病杂志,2003,31(3):165-168. 被引量：100
10The Heart Outcomes Prevention Evaluation Study Investigations.Effects of an angiotension-converting-enzyme inhibitor,ramipril,on cardiovascular events in high-risk patients.N Engl J Med,2000,342:145-15

二级参考文献32

1Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
2Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
3Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.
4Taku T, Toshio H, Hatsuyo K, et al. Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Circulation, 2001,104:376-379.
5Ross R. Atherosclerosis-An inflammatory disease. N Eng J Med, 1999,340: 115-126.
6Goran K Hansson. Immune Mechanism In Atherosclerosis Arteroscler Thromb Vasc Biol . 2001,21:1876-1890.
7Koefig W. Inflammation and coronary heart disease:an overview Cardiol Rev, 2001,9:31-35.
8Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation, 1997,96:396-399.
9Brown DL, Hibbs MS, Kearney M, et al. Identification 92 kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation , 1995, 91: 2125-2131.
10Chalmers J, WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for Management of Hypertension. J Hypertens, 1999,17:151-183.